SG10202011016WA - Dna antibody constructs for use against pseudomonas aeruginosa - Google Patents

Dna antibody constructs for use against pseudomonas aeruginosa

Info

Publication number
SG10202011016WA
SG10202011016WA SG10202011016WA SG10202011016WA SG10202011016WA SG 10202011016W A SG10202011016W A SG 10202011016WA SG 10202011016W A SG10202011016W A SG 10202011016WA SG 10202011016W A SG10202011016W A SG 10202011016WA SG 10202011016W A SG10202011016W A SG 10202011016WA
Authority
SG
Singapore
Prior art keywords
pseudomonas aeruginosa
antibody constructs
use against
against pseudomonas
dna antibody
Prior art date
Application number
SG10202011016WA
Other languages
English (en)
Inventor
David Weiner
Ami Patel
Jian Yan
Original Assignee
Univ Pennsylvania
Wistar Inst
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Wistar Inst, Inovio Pharmaceuticals Inc filed Critical Univ Pennsylvania
Publication of SG10202011016WA publication Critical patent/SG10202011016WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10202011016WA 2016-05-05 2017-05-05 Dna antibody constructs for use against pseudomonas aeruginosa SG10202011016WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662332363P 2016-05-05 2016-05-05

Publications (1)

Publication Number Publication Date
SG10202011016WA true SG10202011016WA (en) 2020-12-30

Family

ID=60203552

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202011016WA SG10202011016WA (en) 2016-05-05 2017-05-05 Dna antibody constructs for use against pseudomonas aeruginosa
SG11201809778TA SG11201809778TA (en) 2016-05-05 2017-05-05 Dna antibody constructs for use against pseudomonas aeruginosa

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201809778TA SG11201809778TA (en) 2016-05-05 2017-05-05 Dna antibody constructs for use against pseudomonas aeruginosa

Country Status (12)

Country Link
US (1) US20190153076A1 (zh)
EP (1) EP3452090A4 (zh)
JP (2) JP2019520085A (zh)
KR (2) KR20230093338A (zh)
CN (1) CN110072554A (zh)
AU (2) AU2017261374B2 (zh)
BR (1) BR112018072716A2 (zh)
CA (1) CA3023094A1 (zh)
EA (1) EA201892525A1 (zh)
MX (1) MX2018013525A (zh)
SG (2) SG10202011016WA (zh)
WO (1) WO2017193101A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102111171B1 (ko) 2011-06-10 2020-05-14 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도
KR102184343B1 (ko) * 2011-11-07 2020-11-30 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법
AU2019215006A1 (en) * 2018-01-31 2020-09-17 Inovio Pharmaceuticals, Inc. Nucleic acid antibody constructs for use against respiratory syncytial virus
US20220324948A1 (en) * 2019-07-31 2022-10-13 The Wistar Institute Of Anatomy And Biology Multivalent dna antibody constructs and use thereof
WO2021022113A1 (en) * 2019-07-31 2021-02-04 The Wistar Institute Of Anatomy And Biology Multivalent dna antibody constructs and use thereof
WO2021244421A1 (en) * 2020-06-01 2021-12-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing pseudomonas pcrv and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2220117A2 (en) * 2007-11-30 2010-08-25 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa
KR102111171B1 (ko) * 2011-06-10 2020-05-14 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도
RU2605390C2 (ru) * 2011-08-23 2016-12-20 Рош Гликарт Аг Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
AU2012304313A1 (en) * 2011-09-08 2014-03-06 University Of Florida Research Foundation, Inc. Materials and methods for modulating immune responses
KR102184343B1 (ko) * 2011-11-07 2020-11-30 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법
EP2776061B1 (en) * 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
AU2013224851B2 (en) * 2012-03-02 2018-03-01 Ablynx Nv Pseudomonas aeruginosa PcrV binding single variable domain antibodies
MX2015005719A (es) * 2012-11-06 2016-01-12 Medimmune Llc Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas.
CN104853782A (zh) * 2012-12-13 2015-08-19 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
WO2015089492A2 (en) * 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
EP3139950A4 (en) * 2014-05-05 2017-12-20 Medimmune, LLC Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療

Also Published As

Publication number Publication date
CN110072554A (zh) 2019-07-30
KR20230093338A (ko) 2023-06-27
JP2023058497A (ja) 2023-04-25
WO2017193101A1 (en) 2017-11-09
AU2024203766A1 (en) 2024-06-27
EA201892525A1 (ru) 2019-04-30
CA3023094A1 (en) 2017-11-09
AU2017261374A1 (en) 2018-12-20
EP3452090A1 (en) 2019-03-13
US20190153076A1 (en) 2019-05-23
AU2017261374B2 (en) 2024-06-20
BR112018072716A2 (pt) 2019-02-19
EP3452090A4 (en) 2019-12-18
MX2018013525A (es) 2019-06-10
KR20190025826A (ko) 2019-03-12
JP2019520085A (ja) 2019-07-18
SG11201809778TA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
HRP20201756T8 (hr) Antitijela koja sadrže modificirane regije teškog lanca
ZA202005652B (en) Sprung coupling
EP3498840A4 (en) ANTI-LAG-3 ANTIBODIES
EP3481869A4 (en) ANTI-CD73 ANTIBODY
GB201601077D0 (en) Antibody molecule
HK1250737A1 (zh) 結合cd79的抗體分子
GB201411420D0 (en) Antibody constructs
EP3140653A4 (en) Direct immunohistochemistry assay
EP3492591A4 (en) ANTI-B7-H4 ANTIBODIES
SG10202011016WA (en) Dna antibody constructs for use against pseudomonas aeruginosa
ZA201900483B (en) Anti-cd19 antibody formulations
IL266857A (en) You will notice antibodies
EP3129476A4 (en) Anti-nme antibody
EP3178931A4 (en) Anti-orai1 antibody
EP3601334A4 (en) DNA ANTIBODY CONSTRUCTS FOR USE AGAINST HIV
IL260083A (en) Antibody against myl9
GB201405856D0 (en) Functional antibody assay
EP3198065A4 (en) Antibody like protein
EP3460343A4 (en) oil heater
ZA202005650B (en) Sprung coupling
ZA202005649B (en) Sprung coupling
EP3469003A4 (en) ANTI-PRL3 ANTIBODIES
AU2016904779A0 (en) Antibody
EP3127922A4 (en) Anti-chondroitin-sulfate-e antibody